ReviewChildren (Basel, Switzerland)2018
Biological Drivers of Wilms Tumor Prognosis and Treatment.
Review in Children (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Patterns of miRNA Expression in Primary and Metastatic Wilms Tumor.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Multi-omics analysis identifies stemness-driven molecular subtypes, prognostic signature, epigenetic target APCDD1, and drug candidate Leflunomide in Wilms tumor.Frontiers in oncology · 2026Article
- Preoperative neutrophil-to-lymphocyte ratio as an early risk-stratification and prognostic biomarker in Wilms tumor: a retrospective study.Frontiers in oncology · 2026Article
- Decoding hub gene networks and miRNA interplay in Wilms tumor pathogenesis and therapeutic sensitivity.American journal of translational research · 2025Article
- The outcomes of children with primary malignant renal tumors: a 14-year single-center experience.BMC cancer · 2024Article
- Bioinformatical analysis of the key differentially expressed genes for screening potential biomarkers in Wilms tumor.Scientific reports · 2023Article
- Article
- Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.Pediatric blood & cancer · 2022Article
- METTL14 gene polymorphisms decrease Wilms tumor susceptibility in Chinese children.BMC cancer · 2021Article
- Implications of cell division cycle associated 4 on the Wilm's tumor cells viability via AKT/mTOR signaling pathway.Renal failure · 2021Article
- miRNA Profiling of Hungarian Regressive Wilms' Tumor Formalin-Fixed Paraffin-Embedded (FFPE) Samples by Quantitative Real-Time Polymerase Chain Reaction (RT-PCR).Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Relapsed Wilms' Tumor Presenting as Metastasis to the Zygoma.Radiology case reports · 2021Article
- Review
- Identification of the potential novel biomarkers as susceptibility gene for Wilms tumor.BMC cancer · 2021Article
- [Effect of piRNA NU13 in regulating biological behaviors of human Wilms tumor cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- The contribution ofJournal of Cancer · 2021Article
- Review
- Insights into the Chemical Biology of Childhood Embryonal Solid Tumors by NMR-Based Metabolomics.Biomolecules · 2019Review
- The coexistence of a Wilms' tumor and renal cell carcinoma in children: a case report and review of the literature.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prior to the 1950s, survival from Wilms tumor (WT) was less than 10%. Today, a child diagnosed with WT has a greater than 90% chance of survival. These gains in survival rates from WT are attributed largely to improvements in multimodal therapy: Enhanced surgical techniques leading to decreased operative mortality, optimization of more effective chemotherapy regimens (specifically, dactinomycin and vincristine), and inclusion of radiation therapy in treatment protocols. More recent improvements in survival, however, can be attributed to a growing understanding of the molecular landscape of Wilms tumor. Particularly, identification of biologic markers portending poor prognosis has facilitated risk stratification to tailor therapy that achieves the best possible outcome with the least possible toxicity. The aim of this review is to (1) outline the specific biologic markers that have been associated with prognosis in WT and (2) provide an overview of the current use of biologic and other factors to stratify risk and assign treatment accordingly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.